Research Insight

Genentech, Inc., a member of the Roche Group, and Biogen Idec announced 24-week results1 from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form2  of the disease. Ocrelizumab demonstrated a significant...

New findings from the longest assessment of any MS-specific treatment show that patients treated earlier with Betaferon® (interferon beta-1b) had a 39.3% relative reduced risk in mortality for the time since randomization in the study (P=0.027), compared with patients...

Sanofi-aventis announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly...

A Novartis Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR®  (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced neuroendocrine tumors (NET) compared to taking...

Boehringer Ingelheim announced today promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35 th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Results from the “LUX-Lung 1” trial...

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment-experienced adult women with HIV-1 to examine gender differences in response to HIV therapy....

Results of the Phase III INSIST study show that Onbrez® Breezhaler® (indacaterol) given once-daily is significantly better at improving lung function and reducing breathlessness than twice-daily salmeterol, one of the current mainstays of treatment for patients with chronic obstructive...